As per recommendations, Bayer will continue to investigate asundexian in a different Phase III trial with stroke patients.
The UK’s Autumn 2023 Statement takes a special interest in revitalising parts of the life sciences scene.
The new scheme will launch in 2024 and aims to save the National Health Service (NHS) £14bn over five years.
The UK government has seen a cabinet reshuffle as the Prime Minister removed Steve Barclay as UK health secretary and replaced him with newcomer, Victoria Atkins.
The deal makes Danish Wiik Pharma the sole distributor of Telix’s prostate cancer imaging agent Illuccix across four European territories.
Give your business an edge with our leading industry insights.
A panel discussion at a Copenhagen conference saw representatives from sponsor organisations sharing their hopes for CROs to take ownership when trials go wrong.
Sponsors have been encouraged to keep their reputations above water and stave off bureaucratic slowdown to clinical trials by meeting clinicians face to face.
BioMarin has seen the label for its achondroplasia drug expand following two clinical trials that saw positive growth in children living with the condition.
The company has said that it is ready to launch a Phase IIa trial with the drug being intended to treat an often painful condition.
The European Commission has issued the firms with fines after they were found to have worked together to fix the sales of an antispasmodic drug.